PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Identification of Racial Disparities (ESMO 2024)
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Background: Black women in the Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreNSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read MoreGene-expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research, Vol 30, Issue 14, July 15 2024 Author: Bottosso et al.
Read MoreGene Expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research OF1–OF11, May 2024 Author: Bottosso et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreImproved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read More
